Kura Oncology, Inc. is a clinical‐stage biopharmaceutical company headquartered in Redwood City, California, focused on discovering and developing precision small‐molecule therapies for the treatment of cancer. The company’s research efforts center on targeting the underlying genetic and molecular drivers of malignancies, with an emphasis on oncology pathways that have historically been difficult to drug.
The company’s lead product candidate, tipifarnib, is a farnesyltransferase inhibitor in late‐stage clinical trials for select head and neck cancers and hematologic malignancies. In addition to tipifarnib, Kura’s pipeline includes investigational agents such as KO-947, a selective ERK inhibitor; KO-428, an oral pan-RAF inhibitor; and KRT-232, an MDM2 inhibitor, each designed to address specific oncogenic mechanisms. These programs are being evaluated across multiple tumor types in North America, Europe and Australia through a combination of mono- and combination-therapy clinical trials.
Founded in 2011, Kura Oncology completed its initial public offering in 2014, raising capital to advance its discovery platform and clinical portfolio. Over the years, the company has forged partnerships with leading academic institutions and leveraged its proprietary chemistry and translational biology capabilities to enrich its R&D pipeline. Kura’s discovery engine integrates genetic insights and biomarker strategies to identify patient populations most likely to benefit from its targeted therapies.
The company is led by President and Chief Executive Officer Jonathan A. Lim, whose background spans both biotech start-ups and established pharmaceutical R&D organizations. Under his leadership, Kura has built a senior management team with deep experience in oncology drug development, regulatory affairs and commercialization. As it progresses toward potential regulatory milestones, Kura continues to expand its global trial footprint and explore strategic collaborations to maximize the impact of its investigational therapies.
AI Generated. May Contain Errors.
Free KURA Stock Alerts